Compile Data Set for Download or QSAR
maximum 50k data
Found 28 Enz. Inhib. hit(s) with all data for entry = 7912
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM50398095(CHEMBL2182043 | US9321738, 2)
Affinity DataIC50:  18nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM50398093(CHEMBL2182046 | US9321738, 6)
Affinity DataIC50:  18nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM50398094(CHEMBL2182044 | US9321738, 11)
Affinity DataIC50:  18nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM50398091(CHEMBL2182049 | US9321738, 12)
Affinity DataIC50:  18.8nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM50398090(CHEMBL2182050 | US9321738, 13)
Affinity DataIC50:  24.5nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM223530(US9321738, 4)
Affinity DataIC50:  46nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM50398096(CHEMBL2182042 | US9321738, 3)
Affinity DataIC50:  48nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM50398089(CHEMBL2182051 | US9321738, 14)
Affinity DataIC50:  58nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 3(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM50398090(CHEMBL2182050 | US9321738, 13)
Affinity DataIC50:  65.7nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM50398112(CHEMBL2182045 | US9321738, 7)
Affinity DataIC50:  70nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 3(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM50398093(CHEMBL2182046 | US9321738, 6)
Affinity DataIC50:  132nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 3(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM223530(US9321738, 4)
Affinity DataIC50:  279nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 3(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM50398095(CHEMBL2182043 | US9321738, 2)
Affinity DataIC50:  2.29E+3nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 3(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM50398091(CHEMBL2182049 | US9321738, 12)
Affinity DataIC50:  2.31E+3nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM50398092(CHEMBL2182047 | US9321738, 5)
Affinity DataIC50:  2.66E+3nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM223532(US9321738, 9)
Affinity DataIC50:  4.45E+3nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 3(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM50398092(CHEMBL2182047 | US9321738, 5)
Affinity DataIC50:  6.31E+3nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 3(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM223532(US9321738, 9)
Affinity DataIC50:  1.84E+4nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 3(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM50398089(CHEMBL2182051 | US9321738, 14)
Affinity DataIC50:  1.86E+4nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM223529(US9321738, 1)
Affinity DataIC50:  2.19E+4nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 3(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM50398096(CHEMBL2182042 | US9321738, 3)
Affinity DataIC50:  2.19E+4nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 3(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM50398094(CHEMBL2182044 | US9321738, 11)
Affinity DataIC50:  2.74E+4nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM223531(US9321738, 8)
Affinity DataIC50: >3.00E+4nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 3(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM223529(US9321738, 1)
Affinity DataIC50: >3.00E+4nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 3(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM223531(US9321738, 8)
Affinity DataIC50: >3.00E+4nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 3(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM50398112(CHEMBL2182045 | US9321738, 7)
Affinity DataIC50: >3.00E+4nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 1(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM223533(US9321738, 10)
Affinity DataIC50: >3.00E+4nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLysophosphatidic acid receptor 3(Homo sapiens (Human))
Hoffmann-La Roche

US Patent
LigandPNGBDBM223533(US9321738, 10)
Affinity DataIC50: >3.00E+4nMT: 2°CAssay Description:Test compounds were prepared by adding 90 μL of HBSS/20 mM HEPES/0.1% BSA buffer to 2 μL of serially diluted compounds. To prepare serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent